McKesson heads into the post-earnings period with a sharp gap between price action and analyst conviction — the stock down nearly 10% on the week, yet the Street uniformly holding Buy-equivalent ratings.
The stock closed at $736.09 on Friday, a 14% retreat from a month ago. The week's decline of 9.6% came directly after the May 7 earnings release, which produced a modest 1% next-day slip that then cascaded further. The print followed a prior quarter — announced in January — that knocked the stock 5.8% in a single session, meaning back-to-back earnings have each extracted meaningful value from what had been a high-quality compounder. The next event is not until August 5, leaving a long stretch for the market to reprice.
Options traders have turned strikingly less defensive in the wake of the sell-off. The put/call ratio has dropped to 0.83, more than two standard deviations below its 20-day average of 0.92 — the most call-heavy reading the options market has produced on this name in the period observed. That is a notable divergence: the stock is near its cheapest point in months, and options buyers are leaning into upside rather than protection. A month ago the PCR was running above 1.18, its 52-week peak. The reversal suggests the market is treating the post-earnings level as an entry point, not a further exit.
Short interest tells a similarly unalarming story. Shorts are below 1.7% of the free float and have been easing — down roughly 6% over the past month. Borrowing costs remain negligible at 0.42%, and availability in the lending pool is wide open, pointing to no crowding or squeeze dynamics. The ORTEX short score of 31 reinforces this: there is no building bearish conviction here from the short side. The price move has been driven by sellers, not short-builders.
The analyst response on Friday crystallised the tension. UBS raised its target to $1,050 — even as the stock trades at $736. JPMorgan trimmed its target to $1,015 from $1,107 but held Overweight. Evercore ISI cut to $850 from $950, also holding Outperform. The consensus mean target of $959 implies roughly 30% upside from current levels, and the analyst recommendation differential ranks in the 97th percentile of the ORTEX universe — meaning hardly any stock carries a more uniformly bullish analyst posture. Valuation multiples have re-rated downward too: the trailing PE has compressed to about 16x, a meaningful step-down from recent levels, and the EV/EBITDA at 12.5x sits at a reasonable entry for a defensive distributor generating revenues above $97 billion quarterly. EPS momentum over 90 days ranks in the 82nd percentile, and historical earnings surprise in the 76th — both suggesting the business has been delivering.
The closest peer, CAH (Cardinal Health, 82% correlation), fell 5.9% on the week, pointing to sector-wide pressure rather than an MCK-specific negative. COR (Cencora) dropped 14.1% over the same stretch — the most among the distributor group — while ENSG lost 6.7%. The whole healthcare distribution cohort is being marked down, likely reflecting ongoing policy and reimbursement uncertainty, which contextualises McKesson's move without fully explaining the size of the drawdown.
The setup going into August is therefore a study in whether the post-earnings price dislocation is a reset or the start of a longer derating: the borrow market is loose, options traders are already calling the bottom, and the analyst community hasn't flinched — but the business needs to demonstrate in Q2 that the earnings weakness was transitory rather than structural.
See the live data behind this article on ORTEX.
Open MCK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
